These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders. Perbellini O; Zamò A; Colarossi S; Zampieri F; Zoppi F; Bonadonna P; Schena D; Artuso A; Martinelli G; Chilosi M; Pizzolo G; Zanotti R Cytometry B Clin Cytom; 2011 Nov; 80(6):362-8. PubMed ID: 21656905 [TBL] [Abstract][Full Text] [Related]
26. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature. Bernd HW; Sotlar K; Lorenzen J; Osieka R; Fabry U; Valent P; Horny HP J Clin Pathol; 2004 Mar; 57(3):324-8. PubMed ID: 14990611 [TBL] [Abstract][Full Text] [Related]
27. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia. Nagai S; Ichikawa M; Takahashi T; Sato H; Yokota H; Oshima K; Izutsu K; Hangaishi A; Kanda Y; Motokura T; Chiba S; Yatomi Y; Kurokawa M Exp Hematol; 2007 Nov; 35(11):1747-52. PubMed ID: 17976525 [TBL] [Abstract][Full Text] [Related]
28. Flow cytometric immunophenotypic analysis of systemic mastocytosis involving bone marrow. Jabbar KJ; Medeiros LJ; Wang SA; Miranda RN; Johnson MR; Verstovsek S; Jorgensen JL Arch Pathol Lab Med; 2014 Sep; 138(9):1210-4. PubMed ID: 25171703 [TBL] [Abstract][Full Text] [Related]
29. Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1. Pullarkat ST; Pullarkat V; Lagoo A; Brynes R; Weiss LM; Bedell V; Chen W; Huang Q; Gaal K; Weisenburger DD; Kim YS Leuk Res; 2013 Nov; 37(11):1572-5. PubMed ID: 24035334 [TBL] [Abstract][Full Text] [Related]
30. Immunophenotyping of mast cells: a sensitive and specific diagnostic tool for systemic mastocytosis. van Daele PL; Beukenkamp BS; Geertsma-Kleinekoort WM; Valk PJ; van Laar JA; van Hagen PM; van der Velden VH Neth J Med; 2009 Apr; 67(4):142-6. PubMed ID: 19581658 [TBL] [Abstract][Full Text] [Related]
31. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114 [TBL] [Abstract][Full Text] [Related]
32. Systemic mastocytosis associated with acute myeloid leukaemia. Kim MJ; Kim MK; Kim YK; Gu MJ Pathology; 2017 Oct; 49(6):652-654. PubMed ID: 28826833 [No Abstract] [Full Text] [Related]
33. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. Hahn HP; Hornick JL Am J Surg Pathol; 2007 Nov; 31(11):1669-76. PubMed ID: 18059223 [TBL] [Abstract][Full Text] [Related]
34. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278 [TBL] [Abstract][Full Text] [Related]
35. Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. Morgado JM; Sánchez-Muñoz L; Teodósio CG; Jara-Acevedo M; Alvarez-Twose I; Matito A; Fernández-Nuñez E; García-Montero A; Orfao A; Escribano L Mod Pathol; 2012 Apr; 25(4):516-21. PubMed ID: 22222639 [TBL] [Abstract][Full Text] [Related]
36. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Morgado JM; Perbellini O; Johnson RC; Teodósio C; Matito A; Álvarez-Twose I; Bonadonna P; Zamò A; Jara-Acevedo M; Mayado A; Garcia-Montero A; Mollejo M; George TI; Zanotti R; Orfao A; Escribano L; Sánchez-Muñoz L Histopathology; 2013 Dec; 63(6):780-7. PubMed ID: 24111625 [TBL] [Abstract][Full Text] [Related]
37. Graft-versus-mastocytosis effect after donor lymphocyte infusion: Proof of principle. Hägglund H; Yavuz AS; Dreimane A; Malm C; Sundin A; Sander B; Nilsson G Eur J Haematol; 2021 Feb; 106(2):290-293. PubMed ID: 33010068 [TBL] [Abstract][Full Text] [Related]
38. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980 [TBL] [Abstract][Full Text] [Related]
39. Systemic mastocytosis. Ozdemir D; Dagdelen S; Erbas T Am J Med Sci; 2011 Nov; 342(5):409-15. PubMed ID: 21629042 [TBL] [Abstract][Full Text] [Related]
40. Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry. Chisholm KM; Merker JD; Gotlib JR; Gitana G; Lefterova M; Zehnder JL; George TI; Arber DA; Ohgami RS Am J Clin Pathol; 2015 Apr; 143(4):527-34. PubMed ID: 25780004 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]